Silverarc Capital Management, LLC
Silverarc Capital Management, LLC reported 65 US-listed holdings worth $898.5 million in its 13F for the quarter ended 30 June 2026, filed 13 August 2026. Its largest: Ascendis Pharma A/s (6.1%), Celcuity Inc. (5.8%) and Cogent Biosciences Inc. (5.5%). Against the quarter before, it opened 20 positions, added to 15, trimmed 27 and sold out of 22.
Reported holdings$898.5M+5.9% on Q1 2026
Positions65-2 on Q1 2026
The largest ten45.3%of its reported holdings
Latest 13FQ2 2026filed 13 August 2026
OpenedAdded toTrimmed
The 14 largest of its 65 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +112.5% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Its reported holdingsThe S&P 500
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Opened 20Added 15Held 3Trimmed 27Sold out 22
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 20
- Ascendis Pharma A/s ASND$55.0 million
- Enliven Therapeutics Inc. ELVN$24.8 million
- Sagimet Biosciences Inc. SGMT$22.6 million
- Definium Therapeutics Inc. DFTX$18.8 million
- Alx Oncology Holdings Inc. ALXO$11.9 million
- Veradermics Inc MANE$11.7 million
- Avalyn Pharma Inc. AVLN$10.9 million
- Aclaris Therapeutics Inc. ACRS$10.3 million
and 12 more in the table below
Added to 15
- Oruka Therapeutics Inc. ORKA+201,894 shares · +134%
- Celcuity Inc. CELC+143,093 shares · +40%
- Veracyte, Inc. VCYT+138,301 shares · +77%
- Immunovant Inc. IMVT+204,860 shares · +49%
- Syndax Pharmaceuticals Inc. SNDX+325,403 shares · +37%
- Ibio Inc. Com IBIO+3.3 million shares · +1458%
- Ovid Therapeutics Inc. OVID+2.1 million shares · +210%
- C4 Therapeutics Inc. CCCC+1.1 million shares · +59%
and 7 more in the table below
Trimmed 27
- Dianthus Therapeutics Inc. DNTH-264,746 shares · -40%
- Monte Rosa Therapeutics Inc. GLUE-893,745 shares · -45%
- Alkermes plc. ALKS-346,820 shares · -75%
- Abivax SA ABVX-132,937 shares · -44%
- Kodiak Sciences Inc. KOD-445,674 shares · -45%
- Zenas Biopharma Inc. ZBIO-626,146 shares · -55%
- Spyre Therapeutics Inc. SYRE-126,659 shares · -68%
- Erasca Inc. ERAS-588,786 shares · -32%
and 19 more in the table below
Sold out of 22
- Kalvista Pharmaceuticals Inc. KALV$57.9 million last quarter
- Nuvalent Inc. NUVL$36.4 million last quarter
- Ascendis Pharma A/s ASND$28.5 million last quarter
- Centessa Pharmaceuticals PLC CNTA$18.5 million last quarter
- Scholar Rock Holding Corporation SRRK$16.7 million last quarter
- CG Oncology Inc. CGON$11.3 million last quarter
- Celldex Therapeutics Inc. CLDX$5.7 million last quarter
- Cytokinetics Inc. CYTK$4.7 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Ascendis Pharma A/s ASND | 206.2K | $55.0 million | 6.12% | new |
| Celcuity Inc. CELC | 501.0K | $52.4 million | 5.83% | +143.1K |
| Cogent Biosciences Inc. COGT | 1.3M | $49.6 million | 5.52% | -33.5K |
| Urogen Pharma Ltd URGN | 1.3M | $47.9 million | 5.33% | -201.1K |
| Immunome Inc. IMNM | 2.0M | $42.7 million | 4.76% | +166.7K |
| Dianthus Therapeutics Inc. DNTH | 390.0K | $38.0 million | 4.23% | -264.7K |
| Rhythm Pharmaceuticals Inc. RYTM | 311.5K | $34.6 million | 3.85% | +5.5K |
| Oruka Therapeutics Inc. ORKA | 352.8K | $33.6 million | 3.74% | +201.9K |
| Monte Rosa Therapeutics Inc. GLUE | 1.1M | $26.8 million | 2.98% | -893.7K |
| Syndax Pharmaceuticals Inc. SNDX | 1.2M | $26.5 million | 2.95% | +325.4K |
| Enliven Therapeutics Inc. ELVN | 489.4K | $24.8 million | 2.76% | new |
| Immunovant Inc. IMVT | 619.1K | $23.9 million | 2.65% | +204.9K |
| Erasca Inc. ERAS | 1.3M | $23.1 million | 2.58% | -588.8K |
| Sagimet Biosciences Inc. SGMT | 2.9M | $22.6 million | 2.52% | new |
| Abivax SA ABVX | 169.6K | $22.6 million | 2.52% | -132.9K |
| Praxis Precision Medicines I PRAX | 65.7K | $22.0 million | 2.45% | -5.9K |
| Kodiak Sciences Inc. KOD | 546.3K | $21.3 million | 2.37% | -445.7K |
| Definium Therapeutics Inc. DFTX | 400.0K | $18.8 million | 2.09% | new |
| Veracyte, Inc. VCYT | 318.0K | $18.7 million | 2.08% | +138.3K |
| Guardant Health Inc. GH | 99.8K | $15.0 million | 1.67% | +1.3K |
| C4 Therapeutics Inc. CCCC | 3.0M | $14.2 million | 1.58% | +1.1M |
| Zenas Biopharma Inc. ZBIO | 509.8K | $12.9 million | 1.44% | -626.1K |
| Trevi Therapeutics Inc. TRVI | 678.1K | $12.6 million | 1.41% | +167.0K |
| Helix Acquisition Corp. III HLXC | 1.2M | $12.5 million | 1.39% | -31.2K |
| Alx Oncology Holdings Inc. ALXO | 5.7M | $11.9 million | 1.32% | new |
| Veradermics Inc MANE | 95.0K | $11.7 million | 1.30% | new |
| Xenon Pharmaceuticals Inc. XENE | 186.8K | $11.3 million | 1.26% | -10.9K |
| Avalyn Pharma Inc. AVLN | 330.5K | $10.9 million | 1.21% | new |
| Biogen Inc. BIIB | 48.1K | $10.4 million | 1.16% | -2.9K |
| Aclaris Therapeutics Inc. ACRS | 1.9M | $10.3 million | 1.15% | new |
| Cerus Corp. CERS | 3.5M | $10.1 million | 1.13% | +296.2K |
| Avalo Therapeutics Inc. AVTX | 500.4K | $9.2 million | 1.03% | new |
| Benitec Biopharma Inc. BNTC | 679.8K | $9.1 million | 1.01% | -37.9K |
| Vaxcyte Inc. PCVX | 145.0K | $8.4 million | 0.94% | +19 |
| Genedx Holdings Corp. WGS | 122.3K | $8.4 million | 0.93% | new |
| Savara Inc. SVRA | 1.4M | $8.3 million | 0.93% | -75.5K |
| Ovid Therapeutics Inc. OVID | 3.1M | $8.3 million | 0.93% | +2.1M |
| Oric Pharmaceuticals Inc. ORIC | 738.9K | $8.0 million | 0.89% | -361.1K |
| Compass Pathways PLC CMPS | 503.4K | $7.1 million | 0.79% | +203.4K |
| Compugen Ltd CGEN | 3.2M | $6.8 million | 0.76% | -131.6K |
| Solid Biosciences Inc. SLDB | 668.5K | $6.7 million | 0.74% | new |
| Ibio Inc. Com IBIO | 3.5M | $6.2 million | 0.69% | +3.3M |
| Disc Medicine Inc. IRON | 82.8K | $6.1 million | 0.67% | -113.2K |
| Alkermes plc. ALKS | 113.5K | $5.9 million | 0.66% | -346.8K |
| Spyre Therapeutics Inc. SYRE | 60.0K | $5.3 million | 0.59% | -126.7K |
| Artiva Biotherapeutics Inc. ARTV | 525.0K | $5.1 million | 0.57% | new |
| Contineum Therapeutics Inc. CTNM | 296.1K | $4.9 million | 0.54% | -5.6K |
| Uniqure NV QURE | 105.0K | $4.8 million | 0.54% | new |
| Research Alliance Corp Iii Ord Shs Cl A RACC | 360.0K | $3.9 million | 0.43% | new |
| Abeona Therapeutics Inc. ABEO | 610.4K | $3.8 million | 0.42% | -38.5K |
| Insmed Inc. INSM | 34.4K | $3.7 million | 0.41% | -1.4K |
| Karyopharm Therapeutics Inc. KPTI | 297.5K | $2.9 million | 0.32% | new |
| CAMP4 Therapeutics Corp. CAMP | 653.6K | $2.9 million | 0.32% | no change |
| Aziyo Biologic ELUT | 2.2M | $2.1 million | 0.24% | -305.0K |
| Revolution Medicines, Inc. RVMD | 10.0K | $1.9 million | 0.21% | new |
| Sionna Therapeutics Inc SION | 42.5K | $1.9 million | 0.21% | +3.1K |
| Tela Bio Inc. TELA | 2.1M | $1.6 million | 0.18% | -122.1K |
| Achieve Life Sciences Inc. ACHV | 227.2K | $1.5 million | 0.17% | new |
| Fractyl Health Inc. GUTS | 1.6M | $1.3 million | 0.14% | -63.6K |
| Connect Biopharma Hldgs Ltd CNTB | 545.0K | $1.3 million | 0.14% | new |
| Crescent Biopharma Inc. CBIO | 59.1K | $1.1 million | 0.12% | -71.4K |
| Cellectar Biosciences Inc. CLRB | 321.7K | $894,404 | 0.10% | new |
| Foghorn Therapeutics Inc. FHTX | 46.0K | $224,358 | 0.02% | new |
| Adagio Med Hldgs Inc. ADGM | 224.4K | $146,193 | 0.02% | -27.6K |
| Rocket Pharmaceuticals Inc. RCKTW | 104.8K | $356 | 0.00% | no change |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read more
Change is shares against its 13F for the quarter before; the 22 it sold out of are in the box above.Options it reported
| Company | Option | Shares under the options | Value of those shares |
|---|---|---|---|
| ARK ETF Trust | Puts | 500.0K | $21.0 million |
| Syndax Pharmaceuticals Inc. | Calls | 693.6K | $15.2 million |
| Oric Pharmaceuticals Inc. | Calls | 682.6K | $7.4 million |
| Monte Rosa Therapeutics Inc. | Calls | 300.0K | $7.3 million |
| Abivax SA | Calls | 50.0K | $6.7 million |
| Kymera Therapeutics Inc. | Puts | 25.0K | $2.9 million |
| Absci Corporation | Puts | 157.6K | $1.8 million |
| Fulcrum Therapeutics Inc. | Calls | 391.9K | $1.4 million |
8 option lines. A 13F lists calls and puts by the shares they cover and what those shares were worth at the quarter's end, not what the options cost; they are not counted in the holdings above.